Literature DB >> 22335513

DNA interstrand cross-linking agents and their chemotherapeutic potential.

L Brulikova1, J Hlavac, P Hradil.   

Abstract

DNA interstrand cross-linking (ICL) agents are an important group of cytotoxic drugs with the capability of binding covalently between two strands of DNA, thereby preventing vital processes such as replication or transcription in dividing cells. In anticancer therapy however, their potential is limited due to the resistance by various mechanisms. In order to develop highly effective antitumor drugs it is necessary to study both effective ICL formations and their subsequent repair mechanisms. This review presents an overview of development over the past decade and the use of both well-known and new DNA interstrand cross-linking agents. Their potential in applications especially as anticancer chemotherapeutics in the framework of current knowledge of repair mechanisms and development of combined chemotherapy is discussed.

Mesh:

Substances:

Year:  2012        PMID: 22335513     DOI: 10.2174/092986712803414295

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Photoswitchable formation of a DNA interstrand cross-link by a coumarin-modified nucleotide.

Authors:  Mohammad Mojibul Haque; Huabing Sun; Shuo Liu; Yinsheng Wang; Xiaohua Peng
Journal:  Angew Chem Int Ed Engl       Date:  2014-05-19       Impact factor: 15.336

Review 2.  The evolving role of DNA inter-strand crosslinks in chemotherapy.

Authors:  Halley B Rycenga; David T Long
Journal:  Curr Opin Pharmacol       Date:  2018-04-18       Impact factor: 5.547

3.  Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.

Authors:  Gang Chen; Hong Qiu; Shan-Dong Ke; Shao-Ming Hu; Shi-Ying Yu; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

4.  Novel amphiphilic cationic porphyrin and its Ag(II) complex as potential anticancer agents.

Authors:  Artak Tovmasyan; Nelli Babayan; David Poghosyan; Kristine Margaryan; Boris Harutyunyan; Rusanna Grigoryan; Natalia Sarkisyan; Ivan Spasojevic; Suren Mamyan; Lida Sahakyan; Rouben Aroutiounian; Robert Ghazaryan; Gennadi Gasparyan
Journal:  J Inorg Biochem       Date:  2014-06-27       Impact factor: 4.155

5.  A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non-Small Cell Lung Cancer Cells.

Authors:  Chi-Wei Chen; Ming-Hsi Wu; Yi-Fan Chen; Tsai-Yi Yen; Yi-Wen Lin; Shu-Hsin Chao; Satishkumar Tala; Tung-Hu Tsai; Tsann-Long Su; Te-Chang Lee
Journal:  Neoplasia       Date:  2016-03-22       Impact factor: 5.715

6.  Chiral tether-mediated stabilization and helix-sense control of complementary metallo-double helices.

Authors:  Miki Horie; Naoki Ousaka; Daisuke Taura; Eiji Yashima
Journal:  Chem Sci       Date:  2014-09-10       Impact factor: 9.825

7.  A Dual-Specific Targeting Approach Based on the Simultaneous Recognition of Duplex and Quadruplex Motifs.

Authors:  Thi Quynh Ngoc Nguyen; Kah Wai Lim; Anh Tuân Phan
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

8.  PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells.

Authors:  Kumar Sanjiv; Chi-Wei Chen; Rajesh Kakadiya; Satishkumar Tala; Sharda Suman; Ming-Hsi Wu; Yen-Hui Chen; Tsann-Long Su; Te-Chang Lee
Journal:  Transl Oncol       Date:  2014-03-04       Impact factor: 4.243

9.  Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.

Authors:  Maja T Tomicic; Ruth Meise; Dorthe Aasland; Nancy Berte; Rebekka Kitzinger; Oliver H Krämer; Bernd Kaina; Markus Christmann
Journal:  Oncotarget       Date:  2015-10-20

10.  Dysfunctional DNA repair pathway via defective FANCD2 gene engenders multifarious exomic and transcriptomic effects in Fanconi anemia.

Authors:  Karthik Raja Velmurugan; Pawel Michalak; Lin Kang; Natalie C Fonville; Harold R Garner
Journal:  Mol Genet Genomic Med       Date:  2018-11-18       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.